NASOPHARYNGEAL CANCINOMA (NPC)

This phase 3 trial tests whether adding immunotherapy to standard treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 802 participants will be split into low-risk and high-risk groups to see if immunotherapy can replace or boost chemotherapy. The …

This study tests a drug called becotatug vedotin for people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after initial chemotherapy and immunotherapy. About 59 participants will receive the drug during and after radiation therapy. The goal is to see if th…

This study tests a combination of three drugs—an EGFR antibody, a PD-1 inhibitor, and chemotherapy—in people whose nasopharyngeal cancer has come back or spread. The goal is to see if this mix can shrink tumors or delay growth better than current options. About 148 adults aged 18…

This study tests a drug called Toripalimab (an immunotherapy) combined with three different types of chemotherapy before standard radiation and chemo for people with advanced nasopharyngeal cancer. The goal is to find which combination works best to keep the cancer from coming ba…

This study compares a lower dose of radiation to the standard dose for people with nasopharyngeal cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects. About 700 adults aged 18-70 with newly diagnosed, untreated cancer …

This study looks at whether using only targeted radiation (IMRT) is safe and works well for people with stage IB nasopharyngeal cancer that does not have high-risk features. Researchers want to see if this approach can control the disease without adding chemotherapy. The study pl…

This study tests whether adding low-dose radiation to a standard chemotherapy and immunotherapy combination can help control advanced nasopharyngeal cancer that has returned or spread. About 55 adults aged 18-65 with this type of cancer will receive the treatment. The goal is to …

This study tests if proton radiation therapy combined with carbon ion therapy works as well as standard photon radiation with carbon ion therapy for people with newly diagnosed nasopharyngeal cancer. About 470 participants will be randomly assigned to one of the two treatment gro…

This study tests a new drug (HMBD-001) combined with standard treatments (cetuximab, with or without docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, skin, or nasopharynx. The goal is to see if the combination is safe and hel…

This study tests whether adding low-dose radiation to standard chemoimmunotherapy can better control liver tumors in people with nasopharyngeal cancer that has spread to the liver. About 26 adults aged 18-70 with newly diagnosed or recurrent liver metastases will receive the comb…

This study tests whether adding Houyanqing Oral Liquid to standard care can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. About 386 adults aged 18-75 who need radiation will be randomly assigned to receive either the herbal…

This study will collect information from 5000 people with nasopharyngeal cancer to improve how doctors predict the disease's course and choose the best treatments. Participants will receive standard care and be followed for 5 years. The goal is to create a more accurate staging s…

This study enrolls 500 nasopharyngeal cancer patients to analyze imaging and immune system markers before and after proton or photon radiation. The goal is to find biological signs that predict how well the treatment works, side effects, and long-term outcomes. Participants must …